Fulgent Genetics Past Earnings Performance

NasdaqGM:FLGT Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	289	-168	128	41
30 Sep 23	286	-64	113	38
30 Jun 23	307	-49	132	35
31 Mar 23	365	-26	139	33
31 Dec 22	619	143	144	29
30 Sep 22	803	272	141	28
30 Jun 22	925	392	118	26
31 Mar 22	953	461	96	25
31 Dec 21	993	507	75	24
30 Sep 21	1,036	569	58	21
30 Jun 21	910	493	48	18
31 Mar 21	773	417	40	15
31 Dec 20	422	214	30	12
30 Sep 20	135	48	21	9
30 Jun 20	44	3	15	7
31 Mar 20	35	0	13	7
31 Dec 19	33	0	12	7
30 Sep 19	30	-2	11	6
30 Jun 19	25	-4	11	6
31 Mar 19	22	-6	10	6
31 Dec 18	21	-6	10	6
30 Sep 18	20	-5	10	5
30 Jun 18	19	-6	10	5
31 Mar 18	18	-5	10	5
31 Dec 17	19	-3	9	4
30 Sep 17	20	0	9	4
30 Jun 17	21	-5	8	4
31 Mar 17	20	-13	7	4
31 Dec 16	18	-14	7	4
30 Sep 16	15	-22	9	6
30 Jun 16	13	-15	7	5
31 Mar 16	11	-6	7	5
31 Dec 15	10	-5	5	4
31 Dec 14	1	-1	1	1

Growing Profit Margin: FLGT is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: FLGT is unprofitable, but has reduced losses over the past 5 years at a rate of 8.8% per year.

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Fulgent Genetics Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Fulgent Genetics, Inc. to Report Q1, 2024 Results on May 03, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Fulgent Genetics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Fulgent Genetics, Inc. to Report Q3, 2023 Results on Nov 03, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Fulgent Genetics, Inc. to Report Q1, 2024 Results on May 03, 2024

Fulgent Genetics, Inc., Annual General Meeting, May 16, 2024

Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024

Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024

Fulgent Genetics: Buy Growth Ahead Below Liquidation Value

Fulgent Genetics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price

COO & President recently sold US$583k worth of stock

COO & President notifies of intention to sell stock

Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?

Fulgent Genetics, Inc. Announces Two Poster Presentations At SITC 2023 Annual Meeting

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Fulgent Genetics, Inc. to Report Q3, 2023 Results on Nov 03, 2023

Price target decreased by 14% to US$36.50

Chief Financial Officer recently sold US$346k worth of stock

Chief Financial Officer notifies of intention to sell stock

Consensus estimates of losses per share improve by 12%

Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?

Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter of 2023 and Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Fulgent Genetics, Inc. Announces Data from a Phase 1/1b Clinical Study of FID-007 in Treating Various Solid Tancers

COO & President notifies of intention to sell stock

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

Fulgent Genetics, Inc. Provides Earnings Guidance for the Second Quarter of 2023 and Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital

Price target decreased by 7.4% to US$41.67

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Fulgent Genetics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Fulgent Genetics, Inc. Appoints Reggie Groves to Its Board of Directors

Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

Chief Financial Officer recently sold US$23k worth of stock

Fulgent Genetics, Inc., Annual General Meeting, May 01, 2023

Chief Financial Officer recently sold US$64k worth of stock

What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

Less than half of directors are independent

Fulgent Genetics, Inc. (NasdaqGM:FLGT) acquire Fulgent Pharma Holdings, Inc for approximately $100 million.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Fulgent Genetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2022

Fulgent Genetics, Inc. Announces Resignation of Leonard Post from the Board and as the Chair of the Nominating and Corporate Governance Committee

Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching

The Klein Law Firm Files Class Action Complaint on Behalf of Shareholders of Fulgent Genetics, Inc

Fulgent Genetics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Wait For Fulgent Genetics To Grow Up

Less than half of directors are independent

Fulgent Genetics, Inc. Announces Resignation of John Bolger from the Board

Pomerantz Law Firm Announces the Filing of A Class Action Against Fulgent Genetics, Inc

We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending

Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly

Chief Financial Officer recently sold US$95k worth of stock

Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2022

Second quarter 2022 earnings released: EPS: US$0.38 (vs US$2.74 in 2Q 2021)

Fulgent Genetics, Inc. Announces Launch of PCR Based Test to Detect Monkeypox

Fulgent Genetics: Poised To Survive Its Post-Covid Hangover

Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement

Fulgent Genetics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Helio Genomics and Fulgent Genetics Announces That American Medical Association Approves A New Category I Cpt® Code for the Helioliver™ Test

Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency

Chief Financial Officer recently sold US$64k worth of stock

Price target decreased to US$91.00

Fulgent Is Putting Its Cash Bonanza To Work

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Fulgent Genetics, Inc. Provides Earning Guidance for Second Quarter of 2022

Fulgent Genetics, Inc. Announces Executive Appointments

These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely

Fulgent Genetics, Inc. Revises Revenue Guidance for the First Quarter Ended March 31, 2022 and Full Year Ended December 31, 2022

Revenue & Expenses Breakdown
Beta